Mesalazin Orion (Mesalazine)

Mesalazine acts by inhibiting the synthesis of prostaglandins and leukotrienes through cyclooxygenase and lipoxygenase blockade. It also scavenges free radicals and modulates immune cell activity, which collectively reduces inflammatory mediators in the colon and promotes mucosal healing.

The specific dose and frequency of Mesalazin Orion are determined by the prescribing clinician based on disease severity, location, and patient response. Healthcare professionals tailor the regimen to each individual, and patients should follow the prescriber's instructions exactly.

Safety data for mesalazine in pregnancy are limited, and the drug is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk. During breastfeeding, caution is advised because mesalazine can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Mesalazin Orion belongs to the aminosalicylate class, which is often used as first‑line therapy for mild to moderate ulcerative colitis. Compared with systemic steroids or biologics, mesalazine offers a topical anti‑inflammatory effect with a lower risk of systemic immunosuppression, making it suitable for maintenance and distal disease.

Mesalazin Orion should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and efficacy.

Mesalazin Orion is a rectal formulation intended for local application. The prescribed dose is typically inserted into the rectum using the supplied applicator or enema device, allowing direct contact with the inflamed mucosa of the distal colon.

Serious risks, though uncommon, include severe allergic reactions such as anaphylaxis, acute severe colitis with bloody diarrhea, hepatotoxicity, and renal dysfunction. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, persistent abdominal pain, or changes in urine output.

Mesalazin Orion is contraindicated in patients with known hypersensitivity to mesalazine or any component of the formulation. It should also be avoided in individuals with severe renal or hepatic impairment unless closely monitored, and in those with active severe infections without appropriate treatment.